Wellington Management Group LLP Acquires New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Wellington Management Group LLP bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 19,723 shares of the company’s stock, valued at approximately $957,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMPH. Weiss Asset Management LP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $4,967,000. Taika Capital LP purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $1,785,000. Point72 DIFC Ltd raised its position in Amphastar Pharmaceuticals by 85.9% in the 3rd quarter. Point72 DIFC Ltd now owns 3,954 shares of the company’s stock valued at $192,000 after purchasing an additional 1,827 shares in the last quarter. Portolan Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock valued at $15,906,000 after buying an additional 218,901 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth about $10,804,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $39.39 on Friday. The stock’s 50-day simple moving average is $46.63 and its 200-day simple moving average is $44.56. The firm has a market capitalization of $1.89 billion, a PE ratio of 13.13, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $60.33.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 7.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now owns 30,471 shares in the company, valued at $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,533 shares of company stock worth $1,987,482 over the last three months. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.